Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK announces positive results from phase III severe asthma trials of depemokimab
Primary endpoints met in SWIFT-1 and SWIFT-2 trials with statistically significant reduction in exacerbations over 52 weeks vs. placebo
Download (PDF - 109.3KB)GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)
GSK pledges to support the Fleming Initiative - an innovative and collaborative approach to develop new AMR interventions.
Download (PDF - 146.9KB)GSK makes a strong start to 2024 with improving outlook for the year
Q1 2024 performance highlights
Download (PDF - 787.0KB)US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Download (PDF - 139.4KB)EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments
GSK has announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin.
Download (PDF - 146.6KB)New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination.
Download (PDF - 186.1KB)GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Prescription Drug User Fee Act action date set by FDA for 14 February 2025.
Download (PDF - 201.1KB)Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.
Download (PDF - 207.9KB)GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma
Trial unblinded early at an interim analysis based on Independent Data Monitoring Committee recommendation
Download (PDF - 185.7KB)ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at CROI.
Download (PDF - 126.1KB)ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Download (PDF - 136.6KB)GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director
GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director.
Download (PDF - 150.6KB)Statement: Zantac (ranitidine) litigation
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord.
Download (PDF - 108.6KB)ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.
Download (PDF - 318.5KB)GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)
EAGLE-1 trial met its primary efficacy endpoint.
Download (PDF - 137.7KB)LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges
Full data set to be presented at an upcoming scientific conference.
Download (PDF - 147.7KB)GSK completes acquisition of Aiolos Bio
GSK has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company.
Download (PDF - 119.6KB)GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
Download (PDF - 189.2KB)GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk
GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.
Download (PDF - 275.7KB)GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration
Shingrix already approved in China for adults aged 50 years and over.
Download (PDF - 145.0KB)